Neogenomics Inc is a leading provider of cancer-focused genetic testing and diagnostic services
The company specializes in developing advanced technologies that enhance the accuracy of cancer diagnosis and treatment planning. Through its comprehensive suite of laboratory services, Neogenomics aids healthcare providers by offering insights into genetic markers associated with various cancers, enabling personalized medicine approaches. In addition to its testing services, Neogenomics is dedicated to research and development, striving to improve and innovate methodologies that contribute to better patient outcomes in oncology.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQNEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.
NeoGenomics, Inc. (NASDAQNEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors, including non-small cell lung cancer.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization.
NeoGenomics, Inc. (NASDAQNEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 10:45 a.m. ET in New York City.
